Episurf Medical to host its first ever educational symposium at the prestigious ICRS Congress in Sorrento, Italy (Nasdaq OMX)
2016-09-21 09:21
An eminent faculty of surgeons and radiologists will lead Episurf Medical’s
first ever educational symposium at the ICRS (International Cartilage Repair
Society) World Congress on Sunday 25th September. The congress is
world-renowned and brings together surgeons and cell biologists who are focused
on treating patients suffering from cartilage pathologies.
This information was published, 2016-09-21 09:21 CEST (GLOBE NEWSWIRE) –
The educational symposium, titled “How to Tailor the Transition between Biology
and Arthroplasty” will be delivered by a panel of four respected clinicians who
specialise in various aspects of cartilage repair. Associate Professor Tim
Spalding, from University Hospitals Coventry and Warwickshire (UK), will chair
the meeting. He will be supported by ex-ICRS President Professor Mats
Brittberg, from Gothenburg (Sweden), Dr Adam Mitchell, from Fortius Clinic,
London (UK) and Professor Leif Ryd, Senior Advisor to Episurf Medical, from
Stockholm (Sweden).
The meeting will discuss the range of options available for treating articular
cartilage lesions of the knee joint and the complexities faced by surgeons. The
session will focus on the place of Episurf’s patented Episealer technology in
the patient treatment algorithm and will include sessions on results, basic
science, the surgical technique and how the MRI processes can be used by a
surgeon to aid their decision making process.
“We are delighted that this world-class group of surgeons and radiologist is
coming together to inform their colleagues about the Episealer technology”,
says Rosemary Cunningham Thomas, CEO of Episurf Medical. “This is a very proud
moment for us. Having these distinguished soft-tissue specialists educating
their colleagues on the science of Epsiealer via their combined clinical
experiences, will help to mainstream Episealer as a valid option in the
surgeon’s treatment algorithm”.
‘’On a daily basis, we see how patients are benefiting from Episealer and we
look forward to working even more closely with surgeons to make a difference
for patient outcomes. The pedigree of the Episealer device for treating
chondral and osteochondral defects will be further supported with the
presentation of 12-month outcome data later in the congress. With a growing
body of impressive clinical outcomes, Episurf Medical is able to meet the
challenges and demands of orthopaedic specialists in the cartilage field”,
concludes Rosemary Cunningham Thomas.